FDA’s Cannabis Advisor: Approach to CBD Rules Shouldn’t Let “Perfect be the Enemy of the Good”
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.
Exclusive: Cannabis Wire Goes One-on-One with FDA’s Leading Advisor on Cannabis
Norm Birenbaum, the FDA’s senior public health advisor on cannabis, spoke with Cannabis Wire about his new role and his priorities for 2023.
FDA Announces Plan to Work with Congress on “New” Path for CBD Products
The cannabis industry has long-awaited rules from the FDA to guide the CBD industry. Now, it’s up to Congress.
Here’s the FDA’s Final Guidance on Cannabis and Clinical Research
The FDA’s long-awaited guidance for non-medical products containing CBD, which are already widely available despite being unregulated, is still in the works.
Attorneys General Call on Congress to Address Cannabis Edibles Packaged Like Popular Brands
The group wants Congress to step in and pass legislation that could curb so-called “copycat” THC products, which are particularly appealing to kids.
Cannabis and Isomers like Delta-8 in Spotlight at Federal Testing Meeting
During the SAMHSA Drug Testing Advisory Board meeting, officials discussed emerging trends with cannabis-derived isomers.
FDA Officials Wrestle with CBD in Day-Long Meeting on Science “Challenges”
The FDA still has more questions than answers on CBD, but it is making strides on conducting the research and collecting the data needed to release product regulations.
FDA Meeting Will Spotlight “Challenges” With Cannabis Compounds in Foods and Supplements
The meeting, which will use cannabinoids as a “case study” in assessing the “safety” of certain foods and supplements, comes as the FDA wrestles with rulemaking for CBD products.
FDA Warns Companies Against CBD in Animal Products
While cannabidiol products aren’t yet FDA approved for humans or animals, that hasn’t stopped plenty of sellers from marketing their products to treat, for example, animals’ anxiety.
Cannabis Testing, Research, and the Future of Federal Regulation
A two-day event hosted by the Food and Drug Law Institute highlighted cannabis regulatory headaches, including delta-8 THC and a lack of uniformity in lab testing.
FDA Commissioner Robert Califf Says He is “Committed” to Finding a “Path” for CBD
The U.S. Food and Drug Administration has been working for years on rules for products containing cannabis-derived compounds like CBD. But nothing has yet materialized.
FDA Researchers Publish First Study on Medical Cannabis Testing Patchwork
The research comes amid a broader agency effort to collect data on cannabinoids, which will help shape forthcoming rules on approved products.
FDA Issues More CBD Warning Letters, With a Focus on Covid Claims
The 2018 Farm Bill legalized hemp, and, by extension, hemp-derived CBD, but the Food and Drug Administration has not yet released rules to guide the growing industry.
FDA Reiterates Need for Cannabinoid Data in Webinar on Research and Regulation
The Food and Drug Administration has said for years that it is working on rules for cannabinoid-containing products. But it has also said that crucial research and data are lacking.
Cannabis is Federally Illegal. But the Groundwork for Federal Regulation is Being Laid
The federal law on cannabis has remained unchanged for more than half a century. Yet as states race toward legalization, federal agencies have begun to play catch up.
FDA: The Cannabis Regulatory Landscape is “Complex”
A policy coordinator with the FDA’s Cannabis Product Committee spoke about CBD during a Food and Drug Law Institute event focused on cannabis.